Advertisement

QuidelOrtho Corporation QDEL

Set alert

Price alert · QDEL

All alert types
13.25 USD -0.51 -3.71%

At close · Oct 30

13.25 0.00 0.00%

After hours · Oct 30, 7:08 PM ET

Bid
13.23 × 2
Ask
13.25 × 2
12.48 Day range 13.51
9.96 52-week range 35.38
YTD
-53.61%
1 year
-50.58%
Open
13.46
Prev close
13.76
Mkt cap
908.62M
Vol
1.74M
Avg vol
1.77M
EPS
-15.39
P/E
0.00
Div yield
0.00%
More statistics
Low
12.48
High
13.51
Forward P/E
10.22
Beta
0.69
Short ratio
10.38
Inst. own
124.87%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
15.81
200-d avg
19.67
1y target
14.67

2Y chart

Chart tools
Interval
QDEL two-year price chart9.9219.829.739.649.5Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
1.01B
Enterprise value
4.00B
Trailing P/E
0.00
Forward P/E
10.22
PEG ratio
2.06
Price / sales
0.38
Price / book
0.57
EPS (TTM)
-15.43
Beta
0.69
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-39.20%
Revenue (TTM)
2.67B
Revenue growth
2.80%
Free cash flow
146.76M
Total cash
123.40M
Total debt
3.08B
Return on equity
-45.91%
Shares outstanding
68.58M
Short % of float
29.75%
50-day average
15.81
200-day average
19.67

Analyst view

Consensus: hold

Hold
Price target (mean) 14.67 +10.7% upside
Target (low)
12.00
Target (mean)
14.67
Target (high)
20.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
  • Strong buy0
  • Buy1
  • Hold1
  • Sell0
  • Strong sell1

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 0.17953.

Earnings history

Financials — quick view

All financials
QDEL Revenue — quarterly 630.90M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
QDEL Net income — quarterly -92.90M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
QDEL EPS — quarterly -1.36
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

QDEL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 28, 20260.18———
Aug 6, 2026Jun 28, 2026-0.048840.13+0.18+366.18%
May 5, 2026Mar 29, 20260.37-0.04-0.41-110.81%
Feb 11, 2026Dec 28, 20250.430.46+0.03+6.98%
Nov 5, 2025Sep 28, 20250.510.80+0.29+56.86%
Aug 5, 2025Jun 29, 20250.001530.12+0.12+7,743.14%

Upgrades / downgrades

QDEL analyst upgrades and downgrades
DateFirmActionFromTo
Jul 8, 2026CitigroupmainNeutralNeutral
Jul 1, 2026JP MorganmainUnderweightUnderweight
May 7, 2026JefferiesdownBuyHold
May 6, 2026CitigroupmainNeutralNeutral
Apr 10, 2026UBSmainNeutralNeutral
Feb 12, 2026CitigroupmainNeutralNeutral

About QuidelOrtho Corporation

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on QDEL — it syncs with the Stock Master app.

Insider holders

QDEL insider holders
InsiderRelationLatest transactionDateShares held
BLASER BRIAN JChief Executive OfficerConversion of Exercise of derivative securityMay 14, 202675,722
BUECHLER KENNETH FDirectorConversion of Exercise of derivative securityJun 4, 2026110,906
BUJARSKI ROBERT JOSEPHChief Operating OfficerConversion of Exercise of derivative securityOct 14, 202444,810
BUSKY JOSEPH MChief Financial OfficerConversion of Exercise of derivative securityMar 26, 202655,108
HODGES MICHELLE AOfficerConversion of Exercise of derivative securityFeb 5, 202641,605
MICHAEL EDWARD LDirectorConversion of Exercise of derivative securityJun 4, 202629,433

Institution ownership

QDEL institution ownership
Holder% heldSharesValueReported
Blackrock Inc.16.34%11,202,523165.13MJun 29, 2026
FMR, LLC10.74%7,363,696108.54MJun 29, 2026
Newtyn Management, Llc9.66%6,625,00097.65MJun 29, 2026
Vanguard Portfolio Management LLC6.03%4,135,46460.96MJun 29, 2026
Neuberger Berman Group, LLC5.15%3,534,61952.10MJun 29, 2026
Invesco Ltd.5.07%3,473,43251.20MJun 29, 2026

Fund ownership

QDEL fund ownership
Holder% heldSharesValueReported
Fidelity Capital Trust-Fidelity Value Fund6.38%4,371,77964.44MJun 29, 2026
iShares Trust-iShares Core S&P Small-Cap ETF6.06%4,153,27761.22MJul 30, 2026
AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund4.40%3,020,11244.52MApr 29, 2026
American Century ETF Trust-Avantis U.S. Small Cap Value ETF4.14%2,836,05041.80MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%2,172,67632.03MMar 30, 2026
iShares Trust-iShares Russell 2000 ETF2.62%1,796,23926.48MJun 29, 2026
Advertisement